Category: Ticker
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated…
Announcing the Patient & Caregiver Engagement Committee for the Annual Conference
We are thrilled to introduce the dedicated members of our Annual Conference Patient & Caregiver Engagement Committee! Since early fall,…
Biomarker Testing and Additional Opinions offers Strength and Hope
In the summer of 2021, Cynthia began experiencing mild heartburn—an unusual symptom for her. When she visited her family doctor,…
2024 Houston Cholangiocarcinoma Symposium
The 2024 Houston Cholangiocarcinoma Symposium is set to convene in Houston, drawing together leading experts, researchers, healthcare professionals, patients, and…
Cholangiocarcinoma Foundation Awards $250,000 Innovation Grant to Advance Rare Cancer Research with Funding from Bachrach Family Foundation
The Cholangiocarcinoma Foundation announced the recipients of the 2024 Innovation Grant, generously funded by the Bachrach Family Foundation. The Cholangiocarcinoma…
$550,000 in research grants awarded by the Cholangiocarcinoma Foundation
The Cholangiocarcinoma Foundation, a nonprofit organization funding novel research for bile duct cancer, has awarded the tenth cycle of funding…